CG Oncology's stock has dropped 40% since its IPO peak, driven by profit-taking and competitive concerns despite promising ...

The consensus price target hints at a 123.3% upside potential for CG Oncology, Inc. (CGON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ...

Andres Y. Maldonado, an analyst from H.C. Wainwright, maintained the Buy rating on CG Oncology, Inc. (CGON – Research Report). The associated ...

Fintel reports that on January 7, 2025, TD Cowen initiated coverage of CG Oncology (NasdaqGS:CGON) with a Buy recommendation. Analyst Price Forecast Suggests 126.12% Upside As of December 23, 2024, ...

In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report), with a ...

Shares of CG Oncology stock opened at $30.20 on Friday. The firm’s 50 day moving average is $32.44 and its 200 day moving average is $34.26. CG Oncology has a 1 year low of $25.77 and a 1 year ...

CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) shares were down 6.9% during mid-day trading on Monday .The stock traded as low as $27.84 and last traded at $27.98. Approximately 108,925 ...

Leonard E. Post, a director at CG Oncology Inc. (NASDAQ:CGON), reported the sale of company shares valued at $34,541, according to a recent SEC filing. The transactions took place... SCHAUMBURG, Ill.

CG Oncology, Inc. is an Irvine, California based late-clinical-stage biopharmaceutical concern focused on the development of cretositimogene for the treatment of non-muscle invasive bladder cancer ...

CG Oncology, Inc. (CGON) closed the last trading session at $29.61, gaining 4.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by ...